Steven E Schild

List of Publications by Year
in descending order

504	25,977	9756	8599
papers	citations	73 h-index	146 g-index

507	507	507	20647
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings, 2008, 83, 584-594.	1.4	2,424
2	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings, 2008, 83, 584-594.	1.4	1,906
3	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncology, The, 2015, 16, 187-199.	5.1	1,625
4	Nonâ€“Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 504-535.	2.3	994
5	Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Nonâ€“Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. Journal of Clinical Oncology, 2017, 35, 56-62.	0.8	557
6	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1464-1472.	2.3	556
7	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 807-821.	2.3	394
8	Malignant peripheral nerve sheath tumor: analysis of treatment outcome. International Journal of Radiation Oncology Biology Physics, 1998, 42, 351-360.	0.4	370
9	Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis. Journal of Clinical Oncology, 2011, 29, 279-286.	0.8	336
10	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 255-264.	2.3	335
11	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 364-380.	1.4	331
12	Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression. Journal of Clinical Oncology, 2005, 23, 3366-3375.	0.8	323
13	Nonâ€“Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 515-524.	2.3	323
14	Prognostic Factors for Local Control and Survival After Radiotherapy of Metastatic Spinal Cord Compression. Journal of Clinical Oncology, 2006, 24, 3388-3393.	0.8	292
15	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 364-380.	1.4	291
16	Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214. Journal of Clinical Oncology, 2011, 29, 272-278.	0.8	290
17	Treatment of Small Cell Lung Cancer. Chest, 2013, 143, e400S-e419S.	0.4	290
18	Pineal parenchymal tumors: Clinical, pathologic, and therapeutic aspects. Cancer, 1993, 72, 870-880.	2.0	234

#	Article	IF	Citations
19	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 2788-2797.	0.8	227
20	The Outcome of Combined-Modality Therapy for Stage III Nonâ€“Small-Cell Lung Cancer in the Elderly. Journal of Clinical Oncology, 2003, 21, 3201-3206.	0.8	223
21	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncology, The, 2013, 14, 619-626.	5.1	203
22	Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncology, The, 2014, 15, 1027-1038.	5.1	200
23	RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2000, 163, 845-850.	0.2	197
24	Final Results of a Prospective Study Comparing the Local Control of Short-Course and Long-Course Radiotherapy for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2011, 79, 524-530.	0.4	184
25	The results of radiotherapy for ependymomas: the mayo clinic experience. International Journal of Radiation Oncology Biology Physics, 1998, 42, 953-958.	0.4	172
26	Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 943-951.	0.4	172
27	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.3	168
28	Central neurocytomas. , 1997, 79, 790-795.		162
29	Nonâ€“Small Cell Lung Cancer, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1738-1761.	2.3	156
30	Histologically confirmed pineal tumors and other germ cell tumors of the brain. , 1996, 78, 2564-2571.		151
31	Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 167-175.	0.4	150
32	Matched Pair Analysis Comparing Surgery Followed By Radiotherapy and Radiotherapy Alone for Metastatic Spinal Cord Compression. Journal of Clinical Oncology, 2010, 28, 3597-3604.	0.8	149
33	Analysis of outcome in patients reirradiated for brain metastases. International Journal of Radiation Oncology Biology Physics, 1996, 34, 585-590.	0.4	143
34	Malignant Pineal Parenchymal Tumors in Adult Patients: Patterns of Care and Prognostic Factors. Neurosurgery, 2002, 51, 44-56.	0.6	133
35	Lung Cancer in the Elderly. Journal of Clinical Oncology, 2007, 25, 1898-1907.	0.8	133
36	The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer, 2008, 112, 157-161.	2.0	133

#	Article	IF	Citations
37	Central neurocytoma: Management recommendations based on a 35-year experience. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1145-1154.	0.4	132
38	Treatment of Non-small Cell Lung Cancer, Stage IIIB. Chest, 2007, 132, 266S-276S.	0.4	130
39	Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic experience. Journal of Surgical Oncology, 2002, 80, 19-25.	0.8	126
40	Consensus Statement on Proton Therapy inÂEarly-Stage and Locally Advanced Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 505-516.	0.4	125
41	The Use of Radiotherapy for Patients with Isolated Elevation of Serum Prostate Specific Antigen Following Radical Prostatectomy. Journal of Urology, 1996, 156, 1725-1729.	0.2	124
42	Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1106-1111.	0.4	119
43	Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. Mayo Clinic Proceedings, 2007, 82, 490-513.	1.4	119
44	Radiation therapy for histologically confirmed primary central nervous system germinoma. International Journal of Radiation Oncology Biology Physics, 1997, 38, 915-923.	0.4	117
45	Analysis of Biochemical Control and Prognostic Factors in Patients Treated With Either Low-Dose Three-Dimensional Conformal Radiation Therapy or High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1053-1058.	0.4	117
46	Should Elderly Nonâ€“Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group. Journal of Clinical Oncology, 2005, 23, 9113-9119.	0.8	116
47	Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring System. Journal of Urology, 2006, 176, 985-990.	0.2	113
48	Prognostic factors differ by tumor stage for small cell lung cancer. Cancer, 2009, 115, 2721-2731.	2.0	105
49	Radiotherapy With 4 Gy Ã— 5 Versus 3 Gy Ã— 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). Journal of Clinical Oncology, 2016, 34, 597-602.	0.8	105
50	Salvage Radiotherapy for Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer: Doseâ€“Response Analysis. International Journal of Radiation Oncology Biology Physics, 2010, 76, 735-740.	0.4	104
51	Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer, 2007, 109, 2515-2521.	2.0	103
52	Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 523-533.	0.4	103
53	A New Scoring System to Predicting the Survival of Patients Treated with Whole-Brain Radiotherapy for Brain Metastases. Strahlentherapie Und Onkologie, 2008, 184, 251-255.	1.0	102
54	A prognostic model for advanced stage nonsmall cell lung cancer. Cancer, 2006, 107, 781-792.	2.0	99

#	Article	IF	Citations
55	Tumor response and progressionâ€free survival as potential surrogate endpoints for overall survival in extensive stage smallâ€cell lung cancer. Cancer, 2011, 117, 1262-1271.	2.0	99
56	Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer 1 1This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Additional participating institutions included Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Meritcare Hospital CCOP, Fargo, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	95
57	A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression. Cancer, 2004, 101, 2687-2692.	2.0	93
58	Preliminary Results of Spinal Cord Compression Recurrence Evaluation (Score-1) Study Comparing Short-Course Versus Long-Course Radiotherapy for Local Control of Malignant Epidural Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2009, 73, 228-234.	0.4	93
59	Movements of the Prostate Due to Rectal and Bladder Distension: Implications for Radiotherapy. Medical Dosimetry, 1993, 18, 13-15.	0.4	92
60	Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Nonâ€“Small-Cell Lung Cancer: NCCTG and SWOG Study N0426. Journal of Clinical Oncology, 2010, 28, 614-619.	0.8	90
61	Outcome After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients With Oligometastases. Journal of Clinical Oncology, 2007, 26, 50-56.	0.8	88
62	Wholeâ€brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer, 2007, 110, 2285-2292.	2.0	88
63	Prognostic value of the MIB-1 labeling index for central neurocytomas. Neurology, 2004, 62, 987-989.	1.5	87
64	Treatment of atypical neurocytomas. Cancer, 2004, 100, 814-817.	2.0	86
65	Charged Particle Radiation Therapy for Uveal Melanoma: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 86, 18-26.	0.4	86
66	Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer, 2010, 116, 3670-3673.	2.0	85
67	The results of radical retropubic prostatectomy and adjuvant therapy for pathologic Stage C prostate cancer. International Journal of Radiation Oncology Biology Physics, 1996, 34, 535-541.	0.4	82
68	Stereotactic radiosurgery for glomus jugulare tumors: A preliminary report. International Journal of Radiation Oncology Biology Physics, 1997, 38, 491-495.	0.4	81
69	Treatment recommendations for the various subgroups of neurocytomas. Journal of Neuro-Oncology, 2006, 77, 305-309.	1.4	81
70	A Score Predicting Posttreatment Ambulatory Status in Patients Irradiated for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2008, 72, 905-908.	0.4	80
71	Surgery Followed by Radiotherapy Versus Radiotherapy Alone for Metastatic Spinal Cord Compression From Unfavorable Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 81, e861-e868.	0.4	78
72	Prognostic factors for functional outcome and survival after reirradiation for inâ€field recurrences of metastatic spinal cord compression. Cancer, 2008, 113, 1090-1096.	2.0	77

#	Article	IF	Citations
73	Therapy of meningeal melanocytomas. Cancer, 2004, 100, 2442-2447.	2.0	76
74	Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer, 2005, 103, 2349-2354.	2.0	76
75	Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Practical Radiation Oncology, 2015, 5, e77-e86.	1.1	75
76	Well-differentiated neurocytoma: What is the best available treatment?. Neuro-Oncology, 2005, 7, 77-83.	0.6	74
77	Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1â€“3 brain metastases: Results of a matched pair analysis. European Journal of Cancer, 2009, 45, 400-404.	1.3	74
78	Dose escalation of radiotherapy for Metastatic Spinal Cord Compression (MSCC) in patients with relatively favorable survival prognosis. Strahlentherapie Und Onkologie, 2011, 187, 729-735.	1.0	74
79	Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. Journal of Urology, 2006, 176, 2020-2024.	0.2	73
80	Locally Advanced Stage IV Squamous Cell Carcinoma of the Head and Neck: Impact of Pre-Radiotherapy Hemoglobin Level and Interruptions During Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1108-1114.	0.4	73
81	Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. Radiotherapy and Oncology, 2019, 141, 56-61.	0.3	71
82	Radiotherapy for Isolated Increases in Serum Prostate-Specific Antigen Levels After Radical Prostatectomy. Mayo Clinic Proceedings, 1994, 69, 613-619.	1.4	70
83	A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer, 2007, 110, 1791-1795.	2.0	69
84	Results of Radiotherapy for Chemodectomas. Mayo Clinic Proceedings, 1992, 67, 537-540.	1.4	68
85	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Nonâ€“Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. Journal of Clinical Oncology, 2017, 35, 2885-2892.	0.8	68
86	Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 5929-5937.	0.8	66
87	Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1452-1457.	0.4	66
88	Postoperative adjuvant therapy of rectal cancer: An analysis of disease control, survival, and prognostic factors. International Journal of Radiation Oncology Biology Physics, 1989, 17, 55-62.	0.4	64
89	The role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer, 2010, 116, 432-442.	2.0	64
90	Results of a Phase II Study of High-Dose Thoracic Radiation Therapy With Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53). Journal of Clinical Oncology, 2007, 25, 3124-3129.	0.8	61

#	Article	IF	Citations
91	Nongerminomatous germ cell tumors of the brain. International Journal of Radiation Oncology Biology Physics, 1996, 36, 557-563.	0.4	60
92	Radiotherapy for Men With Isolated Increase in Serum Prostate Specific Antigen After Radical Prostatectomy. Journal of Urology, 2003, 170, 1833-1837.	0.2	60
93	Treatment of painful bone metastases. Nature Reviews Clinical Oncology, 2010, 7, 220-229.	12.5	60
94	Metastatic ependymoma: A multiâ€institutional retrospective analysis of prognostic factors. Pediatric Blood and Cancer, 2008, 50, 231-235.	0.8	59
95	Robust intensityâ€modulated proton therapy to reduce high linear energy transfer in organs at risk. Medical Physics, 2017, 44, 6138-6147.	1.6	58
96	Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. International Journal of Radiation Oncology Biology Physics, 2006, 64, 182-188.	0.4	57
97	Long-term survival and patterns of failure after postoperative radiation therapy for subtotally resected rectal adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 1989, 16, 459-463.	0.4	56
98	Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. American Journal of Surgery, 2004, 188, 122-125.	0.9	56
99	Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1075-1082.	0.5	56
100	The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer, 2007, 110, 363-368.	2.0	54
101	Scoring Systems to Estimate Intracerebral Control and Survival Rates of Patients Irradiated for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1122-1127.	0.4	54
102	A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. Cancer, 2013, 119, 897-903.	2.0	54
103	Comparison of Short-Course versus Long-Course Whole-Brain Radiotherapy in the Treatment of Brain Metastases. Strahlentherapie Und Onkologie, 2008, 184, 30-35.	1.0	53
104	Value of postoperative stereotactic radiosurgery and conventional radiotherapy for incompletely resected typical neurocytomas. Cancer, 2006, 106, 1140-1143.	2.0	52
105	Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT + SRS) for one to three brain metastases. Strahlentherapie Und Onkologie, 2008, 184, 655-662.	1.0	52
106	Risk of Radiation Retinopathy in Patients With Orbital and Ocular Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1145-1150.	0.4	50
107	Metastatic spinal cord compression in patients with colorectal cancer. Journal of Neuro-Oncology, 1999, 44, 175-180.	1.4	49
108	Radiation dose escalation for localized prostate cancer. Cancer, 2009, 115, 5596-5606.	2.0	49

#	Article	IF	Citations
109	A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904. Journal of Thoracic Oncology, 2013, 8, 1043-1049.	0.5	49
110	The clinical case for proton beam therapy. Radiation Oncology, 2012, 7, 174.	1.2	48
111	The treatment of locally advanced colon cancer. International Journal of Radiation Oncology Biology Physics, 1997, 37, 51-58.	0.4	47
112	Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 751-757.	0.5	47
113	Surgical Resection Followed by Whole Brain Radiotherapy Versus Whole Brain Radiotherapy Alone for Single Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1319-1324.	0.4	46
114	Radiochemotherapy Including Cisplatin Alone versus Cisplatin + 5-Fluorouracil for Locally Advanced Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck. Strahlentherapie Und Onkologie, 2009, 185, 675-681.	1.0	46
115	Brief Report: A Phase II â€œWindow-of-Opportunityâ€•Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study. Journal of Thoracic Oncology, 2012, 7, 919-922.	0.5	46
116	The prognostic impact of tumor cell expression of estrogen receptorâ€Î±, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer, 2012, 118, 157-163.	2.0	46
117	Tonsil cancer. Patterns of failure after surgery alone and surgery combined with postoperative radiation therapy. Cancer, 1994, 73, 2638-2647.	2.0	44
118	A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Nonâ€“Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology, 2013, 8, 79-88.	0.5	44
119	Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 479-489.	0.4	44
120	Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: Do outcomes differ?. Urology, 2004, 64, 760-764.	0.5	43
121	Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncology, 2007, 43, 535-543.	0.8	43
122	Outcome and Toxicity for Patients Treated with Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Journal of Urology, 2013, 190, 521-526.	0.2	43
123	Robust Optimization for Intensity Modulated Proton Therapy to Redistribute High Linear Energy Transfer from Nearby Critical Organs to Tumors in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 181-193.	0.4	43
124	Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 589-598.	0.4	42
125	Reduction of Overall Treatment Time in Patients Irradiated for More Than Three Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1509-1513.	0.4	42
126	Validation of a Score Predicting Post-Treatment Ambulatory Status After Radiotherapy for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1503-1506.	0.4	42

#	Article	IF	Citations
127	Doseâ€“response relationship for fractionated irradiation in the treatment of spinal meningeal melanocytomas: a review of the literature. Journal of Neuro-Oncology, 2006, 77, 311-314.	1.4	41
128	Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer, 2007, 110, 1345-1350.	2.0	41
129	Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer, 2007, 110, 2587-2592.	2.0	41
130	Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. International Journal of Radiation Oncology Biology Physics, 2007, 67, 525-531.	0.4	41
131	A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer, 2012, 12, 302.	1.1	41
132	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e969-e975.	0.9	41
133	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.4	40
134	A boost in addition to wholeâ€brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer, 2007, 110, 1551-1559.	2.0	39
135	Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. International Journal of Radiation Oncology Biology Physics, 2007, 67, 532-537.	0.4	39
136	Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1099-1106.	0.5	39
137	Prophylactic cranial irradiation in elderly patients with small cell lung cancer: Findings from a North Central Cancer Treatment Group pooled analysis. Journal of Geriatric Oncology, 2015, 6, 119-126.	0.5	39
138	Exploratory study of the association of volumetric modulated arc therapy (<scp>VMAT</scp>) plan robustness with local failure in head and neck cancer. Journal of Applied Clinical Medical Physics, 2017, 18, 76-83.	0.8	39
139	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers, 2021, 13, 6193.	1.7	39
140	Effect of Smoking During Radiotherapy, Respiratory Insufficiency, and Hemoglobin Levels on Outcome in Patients Irradiated for Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1134-1142.	0.4	38
141	Doseâ€escalation of wholeâ€brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer, 2012, 118, 3852-3859.	2.0	38
142	Defining the optimal dose of radiation after incomplete resection of central neurocytomas. International Journal of Radiation Oncology Biology Physics, 2003, 55, 373-377.	0.4	37
143	Toxicity of two cisplatinâ€based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head and Neck, 2008, 30, 235-241.	0.9	37
144	Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 3-9.	0.5	37

#	Article	IF	Citations
145	Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlentherapie Und Onkologie, 2011, 187, 626-632.	1.0	36
146	Evaluation of B7-H3 Expression as a Biomarker of Biochemical Recurrence After Salvage Radiation Therapy for Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1343-1349.	0.4	36
147	A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiotherapy and Oncology, 2013, 108, 123-127.	0.3	36
148	Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 109-118.	0.4	35
149	Radiotherapy of metastatic spinal cord compression in very elderly patients. International Journal of Radiation Oncology Biology Physics, 2007, 67, 256-263.	0.4	35
150	Comparison of Four Cisplatin-Based Radiochemotherapy Regimens for Nonmetastatic Stage III/IV Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1037-1044.	0.4	35
151	Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. Lung, 2017, 195, 217-224.	1.4	35
152	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology Biology Physics, 2018, 101, 177-185.	0.4	35
153	Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study. Journal of Thoracic Oncology, 2010, 5, 1346-1353.	0.5	34
154	A frontâ€line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. Cancer, 2010, 116, 5686-5693.	2.0	34
155	Robust optimization in <scp>IMPT</scp> using quadratic objective functions to account for the minimum <scp>MU</scp> constraint. Medical Physics, 2018, 45, 460-469.	1.6	34
156	Acute and Chronic Results of Adjuvant Radiotherapy After Mastectomy and Transverse Rectus Abdominis Myocutaneous (TRAM) Flap Reconstruction for Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 389-394.	0.6	33
157	A Matched-Pair Analysis Comparing Whole-Brain Radiotherapy Plus Stereotactic Radiosurgery Versus Surgery Plus Whole-Brain Radiotherapy and a Boost to the Metastatic Site for One or Two Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1077-1081.	0.4	33
158	Endocavitary radiotherapy of rectal cancer. International Journal of Radiation Oncology Biology Physics, 1996, 34, 677-682.	0.4	32
159	Radiotherapy for Oligometastatic Disease in Patients with Spinal Cord Compression (MSCC) from Relatively Radioresistant Tumors. Strahlentherapie Und Onkologie, 2010, 186, 218-223.	1.0	32
160	Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer â€“ Results of a matched-pair analysis. European Journal of Cancer, 2011, 47, 2729-2734.	1.3	32
161	Smallâ€spot intensityâ€modulated proton therapy and volumetricâ€modulated arc therapies for patients with locally advanced nonâ€smallâ€cell lung cancer: A dosimetric comparative study. Journal of Applied Clinical Medical Physics, 2018, 19, 140-148.	0.8	32
162	The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy. International Journal of Radiation Oncology Biology Physics, 1992, 23, 141-145.	0.4	31

#	Article	IF	Citations
163	Laparoscopic Radical Parametrectomy and Pelvic and Aortic Lymphadenectomy for Vaginal Carcinoma: A Case Report. Gynecologic Oncology, 1999, 75, 514-516.	0.6	31
164	Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer, 2007, 110, 1077-1082.	2.0	31
165	Defining the best available treatment for neurocytomas in children. Cancer, 2004, 101, 2629-2632.	2.0	30
166	Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlentherapie Und Onkologie, 2008, 184, 198-205.	1.0	30
167	Dose Escalation of Whole-Brain Radiotherapy for Brain Metastases From Melanoma. International Journal of Radiation Oncology Biology Physics, 2010, 77, 537-541.	0.4	30
168	Radiation therapy after prostatectomy: Now or later?. Seminars in Radiation Oncology, 1998, 8, 132-139.	1.0	29
169	Radiation therapy (RT) after prostatectomy:The case for salvage therapy as opposed to adjuvant therapy. International Journal of Cancer, 2001, 96, 94-98.	2.3	29
170	Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1530-1535.	0.4	29
171	Robust treatment planning with conditional value at risk chance constraints in intensityâ€modulated proton therapy. Medical Physics, 2017, 44, 28-36.	1.6	29
172	Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 24-29.	0.4	28
173	Vergleich verschiedener Therapieschemata zur Behandlung von 1â€“2 Hirnmetastasen bei Ãlteren Patienten. Strahlentherapie Und Onkologie, 2008, 184, 565-571.	1.0	28
174	Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer, 2010, 10, 582.	1.1	28
175	Dose Escalation for Metastatic Spinal Cord Compression in Patients With Relatively Radioresistant Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1492-1497.	0.4	28
176	Proton beam therapy for locally advanced lung cancer: A review. World Journal of Clinical Oncology, 2014, 5, 568.	0.9	28
177	Whole-Brain Radiotherapy with 20 Gy in 5 Fractions for Brain Metastases in Patients with Cancer of Unknown Primary (CUP). Strahlentherapie Und Onkologie, 2007, 183, 631-636.	1.0	26
178	A new scoring system for predicting survival in patients with nonâ€small cell lung cancer. Cancer Medicine, 2015, 4, 1334-1343.	1.3	26
179	The results of radiotherapy for brainstem tumors. Journal of Neuro-Oncology, 1998, 40, 171-177.	1.4	25
180	Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study. International Journal of Radiation Oncology Biology Physics, 2006, 65, 459-465.	0.4	25

#	Article	IF	Citations
181	Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy, 2009, 8, 309-312.	0.2	25
182	Radiolabeled Cetuximab plus Whole-Brain Irradiation (WBI) for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer (NSCLC). Strahlentherapie Und Onkologie, 2010, 186, 458-462.	1.0	25
183	A randomized trial (RAREST-01) comparing MepitelÂ® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). Radiotherapy and Oncology, 2019, 139, 79-82.	0.3	25
184	In regard to the radiotherapy of myxopapillary ependymomas. International Journal of Radiation Oncology Biology Physics, 2002, 53, 787.	0.4	24
185	Shorter-Course Whole-Brain Radiotherapy for Brain Metastases in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2011, 81, e469-e473.	0.4	23
186	Malignant epidural spinal cord compression. Current Opinion in Supportive and Palliative Care, 2012, 6, 103-108.	0.5	23
187	Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy. Cancer, 2005, 103, 1740-1746.	2.0	22
188	Short-Course Radiotherapy (RT) for Metastatic Spinal Cord Compression (MSCC) Due to Renal Cell Carcinoma: Results of a Retrospective Multi-Center Study. European Urology, 2006, 49, 846-852.	0.9	22
189	Prognostic Factors Affecting Locally Recurrent Rectal Cancer and Clinical Significance of Hemoglobin. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1087-1093.	0.4	22
190	The Impact of Tumor Expression of Erythropoietin Receptors and Erythropoietin on Clinical Outcome of Esophageal Cancer Patients Treated With Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2008, 71, 152-159.	0.4	22
191	Radioactive EGFR Antibody Cetuximab in Multimodal Cancer Treatment: Stability and Synergistic Effects With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1226-1231.	0.4	22
192	Do Patients Receiving Whole-Brain Radiotherapy for Brain Metastases From Renal Cell Carcinoma Benefit From Escalation of the Radiation Dose?. International Journal of Radiation Oncology Biology Physics, 2010, 78, 398-403.	0.4	22
193	Prognostic factors for different outcomes in patients with metastatic spinal cord compression from cancer of unknown primary. BMC Cancer, 2012, 12, 261.	1.1	22
194	Comparison of weekly administration of cisplatin versus three courses of cisplatin 100Âmg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers. BMC Cancer, 2016, 16, 437.	1.1	22
195	Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. Journal of Oncology Practice, 2017, 13, 732-738.	2.5	22
196	Dose Escalation in Patients Receiving Whole-Brain Radiotherapy for Brain Metastases from Colorectal Cancer. Strahlentherapie Und Onkologie, 2010, 186, 70-75.	1.0	21
197	The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clinical Neurology and Neurosurgery, 2013, 115, 2029-2032.	0.6	21
198	A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone. Radiation Oncology, 2014, 9, 215.	1.2	21

#	Article	IF	Citations
199	Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. Radiology and Oncology, 2016, 50, 337-340.	0.6	21
200	Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1078-1082.	0.4	21
201	Endocavitary Radiation Therapy for Rectal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 508-512.	0.6	20
202	Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. European Journal of Cancer, 2006, 42, 1052-1056.	1.3	20
203	D7-07: A phase II NCCTG â€œWindow of Opportunity Front-lineâ€•study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC. Journal of Thoracic Oncology, 2007, 2, S413.	0.5	20
204	Elective Nodal Irradiation (ENI) Doesn't Appear to Provide a Clear Benefit for Patients With Unresectable Nonâ€“Small-Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2008, 72, 311-312.	0.4	20
205	Single brain metastasis: Resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. Clinical Neurology and Neurosurgery, 2012, 114, 326-330.	0.6	20
206	A new score predicting the survival of patients with spinal cord compression from myeloma. BMC Cancer, 2012, 12, 425.	1.1	20
207	Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. Practical Radiation Oncology, 2016, 6, e269-e275.	1.1	20
208	Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations. Medical Physics, 2020, 47, 745-752.	1.6	20
209	Intensityâ€•modulated proton therapy (IMPT) interplay effect evaluation of asymmetric breathing with simultaneous uncertainty considerations in patients with nonâ€•small cell lung cancer. Medical Physics, 2020, 47, 5428-5440.	1.6	20
210	Radiotherapy Treatment Planning for Prostate Cancer in Patients with Prosthetic Hips. Medical Dosimetry, 1992, 17, 83-86.	0.4	19
211	Brain Metastases From Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 633-636.	0.6	19
212	Image-Guided Radiotherapy for Prostate Cancer: A Prospective Trial of Concomitant Boost Using Indium-111â€“Capromab Pendetide (ProstaScint) Imaging. International Journal of Radiation Oncology Biology Physics, 2011, 81, e423-e429.	0.4	19
213	Single brain metastasis: Radiosurgery alone compared with radiosurgery plus upâ€•front wholeâ€•brain radiotherapy. Cancer, 2012, 118, 2980-2985.	2.0	19
214	Single brain metastasis: wholeâ€•brain irradiation plus either radiosurgery or neurosurgical resection. Cancer, 2012, 118, 1138-1144.	2.0	19
215	Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Nonâ€“Small Cell Lung Cancer: The Mayo Clinic Experience. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 40-48.	1.2	19
216	Technical Note: Treatment planning system (TPS) approximations matter â€” comparing intensityâ€•modulated proton therapy (IMPT) plan quality and robustness between a commercial and an inâ€•house developed TPS for nonsmall cell lung cancer (NSCLC). Medical Physics, 2019, 46, 4755-4762.	1.6	19

#	Article	IF	Citations
217	Results of <scp>NCCTG</scp> N0275 (Alliance) â€“ a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Medicine, 2016, 5, 1890-1896.	1.3	18
218	Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience. Advances in Radiation Oncology, 2020, 5, 450-458.	0.6	18
219	Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 780-789.	0.4	18
220	Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. Journal of Cancer Therapy, 2017, 08, 73-85.	0.1	18
221	Rectal cancer: preoperative versus postoperative irradiation as a component of adjuvant treatment. Seminars in Radiation Oncology, 2003, 13, 419-432.	1.0	17
222	Evaluation of Ki-67 Staining Levels as an Independent Biomarker of Biochemical Recurrence After Salvage Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1364-1370.	0.4	17
223	Fibroblast Growth Factor 2â€"A Predictor of Outcome for Patients Irradiated for Stage II-III Nonâ€"Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 442-447.	0.4	17
224	Single-Fraction Versus 5-Fraction Radiation Therapy for Metastatic Epidural Spinal Cord Compression in Patients With Limited Survival Prognoses: Results of a Matched-Pair Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 93, 368-372.	0.4	17
225	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for StageÂIIIÂNSCLC. Journal of Thoracic Oncology, 2018, 13, 1171-1182.	0.5	17
226	Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 60-63.	0.4	16
227	Radio(chemo)therapy Plus Resection Versus Radio(chemo)therapy Alone for the Treatment of Stage III Esophageal Cancer*. Strahlentherapie Und Onkologie, 2007, 183, 10-16.	1.0	16
228	Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck. Strahlentherapie Und Onkologie, 2011, 187, 541-547.	1.0	16
229	Impact of disease progression date determination on progressionâ€free survival estimates in advanced lung cancer. Cancer, 2012, 118, 5358-5365.	2.0	16
230	Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Nonâ€"Small Cell Lung Cancer: NCCTG N0028 (Alliance). Journal of Thoracic Oncology, 2017, 12, 697-703.	0.5	16
231	A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy. In Vivo, 2018, 32, 825-828.	0.6	16
232	A novel and individualized robust optimization method using normalized dose interval volume constraints (<scp>NDIVC</scp>) for intensityâ€modulated proton radiotherapy. Medical Physics, 2019, 46, 382-393.	1.6	16
233	Evaluation of Serum Prostate-Specific Antigen Levels After Postoperative Radiation Therapy for Pathologic Stage T3, N0 Prostate Cancer. Mayo Clinic Proceedings, 1996, 71, 242-248.	1.4	15
234	Is 50 Gy Sufficient to Achieve Long-Term Local Control after Incomplete Resection of Typical Neurocytomas?. Strahlentherapie Und Onkologie, 2006, 182, 415-418.	1.0	15

#	Article	IF	Citations
235	Impact of VEGF and VEGF Receptor 1 (FLT1) Expression on the Prognosis of Stage III Esophageal Cancer Patients after Radiochemotherapy*. Strahlentherapie Und Onkologie, 2008, 184, 416-420.	1.0	15
236	Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 686-696.	0.4	15
237	Small-cell Lung Cancer in Very Elderly (â‰¥ 80 Years) Patients. Clinical Lung Cancer, 2019, 20, 313-321.	1.1	15
238	Clinical Validation of a Ray-Casting Analytical Dose Engine for Spot Scanning Proton Delivery Systems. Technology in Cancer Research and Treatment, 2019, 18, 153303381988718.	0.8	15
239	Beam angle comparison for distal esophageal carcinoma patients treated with intensityâ€modulated proton therapy. Journal of Applied Clinical Medical Physics, 2020, 21, 141-152.	0.8	15
240	Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT). International Journal of Radiation Oncology Biology Physics, 2021, 110, 1189-1199.	0.4	15
241	The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1432-1437.	0.4	14
242	Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). Strahlentherapie Und Onkologie, 2010, 186, 307-314.	1.0	14
243	Prognostic Impact of Erythropoietin Expression and Erythropoietin Receptor Expression on Locoregional Control and Survival of Patients Irradiated for Stage II/III Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 499-505.	0.4	14
244	Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression. Clinical Neurology and Neurosurgery, 2014, 118, 12-15.	0.6	14
245	A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. Radiation Oncology, 2017, 12, 69.	1.2	14
246	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limitedâ€stage small cell lung cancer in elderly patients versus younger patients. Cancer, 2019, 125, 382-390.	2.0	14
247	Technical Note: 4D robust optimization in small spot intensityâ€modulated proton therapy (IMPT) for distal esophageal carcinoma. Medical Physics, 2021, 48, 4636-4647.	1.6	14
248	Sleep Disorders Before and During the COVID-19 Pandemic in Patients Assigned to Adjuvant Radiotherapy for Breast Cancer. In Vivo, 2021, 35, 2253-2260.	0.6	14
249	Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. Journal of Thoracic Oncology, 2006, 1, 556-563.	0.5	14
250	Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer. Anticancer Research, 2017, 37, 2693-2696.	0.5	14
251	Improved Posttreatment Functional Outcome is Associated with Better Survival in Patients Irradiated for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1506-1509.	0.4	13
252	Experiences with a New High-Dose-Rate Brachytherapy (HDR-BT) Boost Technique for T3b Prostate Cancer. Strahlentherapie Und Onkologie, 2007, 183, 398-402.	1.0	13

#	Article	IF	Citations
253	Role of radiation therapy in the treatment of melanoma. Expert Review of Anticancer Therapy, 2009, 9, 583-586.	1.1	13
254	Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m 2 cisplatin on five days every four weeks an alternative to 100 mg/m 2 cisplatin every three weeks?. Oral Oncology, 2016, 59, 67-72.	0.8	13
255	Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. European Archives of Oto-Rhino-Laryngology, 2017, 274, 1021-1027.	0.8	13
256	Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease. Clinical Lung Cancer, 2018, 19, e417-e420.	1.1	13
257	An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer. Anticancer Research, 2018, 38, 3753-3756.	0.5	13
258	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 298-303.	0.5	13
259	Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. Reviews in Urology, 2014, 16, 67-75.	0.9	13
260	Radiosurgery with 20 Gy provides better local contol of 1-3 brain metastases from breast cancer than with lower doses. Anticancer Research, 2015, 35, 333-6.	0.5	13
261	Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Research, 2015, 35, 3571-4.	0.5	13
262	Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis (ORN) in Head and Neck Cancer Patients Treated With Pencil-Beam-Scanning Proton Therapy (PBSPT): A Retrospective, Case-Matched Cohort Study. Frontiers in Oncology, 2022, 12, 843175.	1.3	13
263	Epoetin-Î± during radiotherapy for stage III esophageal carcinoma. Cancer, 2005, 103, 2274-2279.	2.0	12
264	Do Bladder Cancer Patients with Metastatic Spinal Cord Compression Benefit from Radiotherapy Alone?. Urology, 2007, 69, 1081-1085.	0.5	12
265	Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT)Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. OMICS Journal of Radiology, 2014, 02, .	0.0	12
266	Stereotactic radiosurgery for newly diagnosed brain metastases. Strahlentherapie Und Onkologie, 2014, 190, 786-791.	1.0	12
267	Perâ€voxel constraints to minimize hot spots in linear energy transferâ€guided robust optimization for base of skull head and neck cancer patients in IMPT. Medical Physics, 2022, 49, 632-647.	1.6	12
268	Clinical necessity of multi-image based (4DMIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy â€“ A comprehensive review. Radiotherapy and Oncology, 2022, 169, 77-85.	0.3	12
269	Innovations in the Radiotherapy of Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 85-92.	0.5	11
270	Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 995-1001.	0.4	11

#	Article	IF	Citations
271	Hypofractionated Whole-Brain Radiotherapy for Multiple Brain Metastases From Transitional Cell Carcinoma of the Bladder. International Journal of Radiation Oncology Biology Physics, 2010, 78, 404-408.	0.4	11
272	A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. Radiation Oncology, 2015, 10, 173.	1.2	11
273	Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?. Oral Oncology, 2016, 57, 40-45.	0.8	11
274	A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. Clinical Lung Cancer, 2016, 17, 558-562.	1.1	11
275	A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1021-1025.	0.4	11
276	A Tool to Predict the Probability of Intracerebral Recurrence or New Cerebral Metastases After Whole-brain Irradiation in Patients with Head-and-Neck Cancer. Anticancer Research, 2018, 38, 4199-4202.	0.5	11
277	Consensus Statement on Proton Therapy in Mesothelioma. Practical Radiation Oncology, 2021, 11, 119-133.	1.1	11
278	Radiation recall dermatitis: A review of the literature. Seminars in Oncology, 2022, 49, 152-159.	0.8	11
279	Doseâ€“effect relationship for radiotherapy after incomplete resection of atypical neurocytomas. Radiotherapy and Oncology, 2005, 74, 67-69.	0.3	10
280	1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. Radiation Oncology, 2018, 13, 21.	1.2	10
281	Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 322-329.	1.1	10
282	Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases. BMC Cancer, 2019, 19, 1156.	1.1	10
283	Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. In Vivo, 2021, 35, 411-415.	0.6	10
284	Comparison of 5â€‰Ã—â€‰5ÂGy and 10â€‰Ã—â€‰3ÂGy for metastatic spinal cord compression using data from three prospective trials. Radiation Oncology, 2021, 16, 7.	1.2	10
285	GPUâ€accelerated Monte Carloâ€based online adaptive proton therapy: A feasibility study. Medical Physics, 2022, 49, 3550-3563.	1.6	10
286	Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clinical Lung Cancer, 2022, 23, e317-e320.	1.1	10
287	O-238 The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. Lung Cancer, 2003, 41, S70.	0.9	9
288	Innovations in the Radiotherapy of Non???Small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 85-92.	0.5	9

#	Article	IF	Citations
289	Short-course whole-brain radiotherapy (WBRT) for brain metastases due to small-cell lung cancer (SCLC). Clinical Neurology and Neurosurgery, 2010, 112, 183-187.	0.6	9
290	Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancerâ€"A retrospective analysis. Journal of Geriatric Oncology, 2012, 3, 104-110.	0.5	9
291	Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Prostate, 2012, 72, 1757-1766.	1.2	9
292	Metastatic spinal cord compression. Strahlentherapie Und Onkologie, 2014, 190, 919-924.	1.0	9
293	A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. BMC Cancer, 2017, 17, 30.	1.1	9
294	Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature. Frontiers in Oncology, 2017, 7, 228.	1.3	9
295	Patient-Reported Outcomesâ€"Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy Ã— 5 to 3 Gy Ã— 10 for Metastatic Epidural Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2019, 105, 760-764.	0.4	9
296	A New Diagnosis-Specific Survival Score for Patients to be Irradiated for Brain Metastases from Non-small Cell Lung Cancer. Lung, 2019, 197, 321-326.	1.4	9
297	Re-Irradiation for Recurrent Glioblastoma Multiforme. Anticancer Research, 2020, 40, 7077-7081.	0.5	9
298	Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of aÂrandomized phaseÂ2 trial (LEOPARD-2). Strahlentherapie Und Onkologie, 2020, 196, 795-804.	1.0	9
299	Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases. In Vivo, 2018, 32, 381-384.	0.6	9
300	Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. Anticancer Research, 2014, 34, 5079-82.	0.5	9
301	THE ROLE OF RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 629-637.	0.8	8
302	Is surgery necessary following chemoradiation for patients with locally advanced cancer of the esophagus?. Nature Clinical Practice Oncology, 2007, 4, 506-507.	4.3	8
303	Prognostic factors for survival and intracerebral control after irradiation for brain metastases from gynecological cancer. Gynecologic Oncology, 2009, 114, 506-508.	0.6	8
304	Radiation Therapy Modalities for Prostate Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 450.	3.8	8
305	Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade â‰¥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS Journal of Radiology, 2016, 5, .	0.0	8
306	Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). Journal of Thoracic Oncology, 2016, 11, 361-369.	0.5	8

#	Article	IF	Citations
307	Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer. Lung, 2016, 194, 295-298.	1.4	8
308	GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. British Journal of Radiology, 2017, 90, 20170174.	1.0	8
309	A New Scoring Tool to Assess Overall Survival in Patients With Intracerebral Metastases From Gynecological Cancers. International Journal of Gynecological Cancer, 2017, 27, 597-602.	1.2	8
310	The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Nonâ€“Small-Cell Lung Cancer Continues. Journal of Clinical Oncology, 2019, 37, 2697-2699.	0.8	8
311	Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer. Anticancer Research, 2021, 41, 4439-4442.	0.5	8
312	Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. Journal of Thoracic Oncology, 2006, 1, 556-563.	0.5	7
313	A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. BMC Cancer, 2014, 14, 589.	1.1	7
314	A New Tool Predicting Survival After Radiosurgery Alone for One or Two Cerebral Metastases from Lung Cancer. Lung, 2015, 193, 299-302.	1.4	7
315	A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung Cancers. Lung, 2016, 194, 625-629.	1.4	7
316	A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. BMC Cancer, 2016, 16, 292.	1.1	7
317	Mixed integer programming with doseâ€volume constraints in intensityâ€modulated proton therapy. Journal of Applied Clinical Medical Physics, 2017, 18, 29-35.	0.8	7
318	Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases. Cancers, 2019, 11, 233.	1.7	7
319	Linear accelerator-based single-fraction stereotactic body radiotherapy for symptomatic vertebral body hemangiomas: The Mayo Clinic experience. Journal of Clinical Neuroscience, 2020, 80, 74-78.	0.8	7
320	Accelerated Fractionation Plus Chemotherapy Versus Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer. Anticancer Research, 2021, 41, 877-884.	0.5	7
321	Comparison of 20Ã—2 Gy and 12Ã—3 Gy for Whole-brain Irradiation of Multiple Brain Metastases from Malignant Melanoma. In Vivo, 2016, 30, 917-920.	0.6	7
322	Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. Anticancer Research, 2016, 36, 1825-8.	0.5	7
323	Radiotherapy with or without Decompressive Surgery for Metastatic Spinal Cord Compression: A Retrospective Matched-Pair Study Including Data from Prospectively Evaluated Patients. Cancers, 2022, 14, 1260.	1.7	7
324	Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?. Nature Clinical Practice Oncology, 2007, 4, 400-401.	4.3	6

#	Article	IF	Citations
325	The number of involved extracranial organs: A new predictor of survival in breast cancer patients with brain metastasis. Clinical Neurology and Neurosurgery, 2013, 115, 2108-2110.	0.6	6
326	Do patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery?. Radiation Oncology, 2014, 9, 267.	1.2	6
327	A Prognostic Instrument to Estimate the Survival of Elderly Patients Irradiated for Metastatic Epidural Spinal Cord Compression From Lung Cancer. Clinical Lung Cancer, 2016, 17, 279-284.	1.1	6
328	A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers. Anticancer Research, 2018, 38, 6877-6880.	0.5	6
329	Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter?. Anticancer Research, 2018, 38, 6835-6840.	0.5	6
330	Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer. Anticancer Research, 2018, 38, 5371-5377.	0.5	6
331	Detecting spatial susceptibility to cardiac toxicity of radiation therapy for lung cancer. IISE Transactions on Healthcare Systems Engineering, 2020, 10, 243-250.	1.2	6
332	Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations. Journal of Thoracic Disease, 2021, 13, 1270-1285.	0.6	6
333	Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN). Anticancer Research, 2021, 41, 477-484.	0.5	6
334	A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy. International Journal of Particle Therapy, 2016, 3, 398-406.	0.9	6
335	Development of a Survival Score for Patients with Cerebral Metastases from Melanoma. Anticancer Research, 2017, 37, 249-252.	0.5	6
336	Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer. Anticancer Research, 2017, 37, 1485-1488.	0.5	6
337	Stereotactic Radiosurgery Alone for One to Two Brain Metastases from Cancer of Unknown Primary. Anticancer Research, 2018, 38, 565-567.	0.5	6
338	Predictive Factors for Local Control and Survival in Patients with Cancer of Unknown Primary (CUP) Irradiated for Cerebral Metastases. Anticancer Research, 2018, 38, 2415-2418.	0.5	6
339	Outcomes After Irradiation of Epidural Spinal Cord Compression Due to Metastatic Thyroid Cancer. Anticancer Research, 2016, 36, 2035-9.	0.5	6
340	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.4	6
341	Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers. Anticancer Research, 2022, 42, 2657-2663.	0.5	6
342	The role of retrograde urethrography in the planning of prostate cancer radiotherapy. Medical Dosimetry, 1997, 22, 83-86.	0.4	5

#	Article	IF	Citations
343	Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 729-734.	0.4	5
344	Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Medical Dosimetry, 2004, 29, 196-203.	0.4	5
345	Radiotherapy for a rising PSA following radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 57-61.	0.8	5
346	Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis. Oral Oncology, 2010, 46, 549-552.	0.8	5
347	Re: Proton vs Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal of the National Cancer Institute, 2013, 105, 748-748.	3.0	5
348	Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck. Strahlentherapie Und Onkologie, 2014, 190, 1021-1027.	1.0	5
349	Number of cerebral lesions predicts freedom from new brain metastases after radiosurgery alone in lung cancer patients. Oncology Letters, 2015, 10, 1109-1112.	0.8	5
350	Predicting the survival probability of gastric cancer patients developing metastatic epidural spinal cord compression (MESCC). Gastric Cancer, 2015, 18, 881-884.	2.7	5
351	Data collection of patient outcomes: one institutionâ€™s experience. Journal of Radiation Research, 2018, 59, i19-i24.	0.8	5
352	Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool. Anticancer Research, 2019, 39, 2091-2095.	0.5	5
353	An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer. Translational Lung Cancer Research, 2020, 9, 1067-1073.	1.3	5
354	Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer. Anticancer Research, 2020, 40, 1665-1668.	0.5	5
355	Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis. Anticancer Research, 2020, 40, 3961-3965.	0.5	5
356	An Easy-To-Use Survival Score Compared to Existing Tools for Older Patients with Cerebral Metastases from Colorectal Cancer. Cancers, 2020, 12, 833.	1.7	5
357	Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer. Anticancer Research, 2021, 41, 5065-5069.	0.5	5
358	Emotional Problems Prior to Adjuvant Radiation Therapy for Breast Cancer. In Vivo, 2021, 35, 2763-2770.	0.6	5
359	A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies. Anticancer Research, 2016, 36, 5469-5472.	0.5	5
360	Sleep Disturbances in Lung Cancer Patients Assigned to Definitive or Adjuvant Irradiation. In Vivo, 2021, 35, 3333-3337.	0.6	5

#	Article	IF	Citations
361	Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. Anticancer Research, 2016, 36, 5463-5468.	0.5	5
362	A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer. Anticancer Research, 2017, 37, 1481-1484.	0.5	5
363	A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer. In Vivo, 2017, 31, 745-748.	0.6	5
364	Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder. In Vivo, 2018, 32, 633-636.	0.6	5
365	A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy. Anticancer Research, 2018, 38, 3111-3114.	0.5	5
366	Innovations in the radiotherapy of non-small cell lung cancer. Journal of Thoracic Oncology, 2006, 1, 85-92.	0.5	5
367	Metastatic spinal cord compression from pancreatic cancer. Anticancer Research, 2014, 34, 3727-30.	0.5	5
368	Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. Anticancer Research, 2014, 34, 5589-92.	0.5	5
369	Predicting Survival After Irradiation of Metastases from Pancreatic Cancer. Anticancer Research, 2015, 35, 4105-8.	0.5	5
370	A Survival Score for Patients Receiving Stereotactic Radiosurgery Alone for Brain Metastases from Breast Cancer. Anticancer Research, 2016, 36, 1073-6.	0.5	5
371	Radiation Therapy Alone Provides Excellent Outcomes for Spinal Cord Compression from Vertebral Lymphoma. Anticancer Research, 2016, 36, 3081-3.	0.5	5
372	A New and Easy-to-Use Survival Score for Patients Irradiated for Metastatic Epidural Spinal Cord Compression. Practical Radiation Oncology, 2022, 12, 354-362.	1.1	5
373	Benign central neurocytoma a double misnomer?. Cancer, 2002, 94, 284-284.	2.0	4
374	The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: Implications for the future. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 1441-1444.	0.7	4
375	Radiochemotherapy for locally advanced squamous cell carcinoma ofÂthe head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 1436-1440.	0.7	4
376	Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer. In Vivo, 2018, 32, 1481-1484.	0.6	4
377	Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer. Anticancer Research, 2018, 38, 6897-6903.	0.5	4
378	Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with â‰¥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer. Anticancer Research, 2018, 38, 3653-3656.	0.5	4

#	Article	IF	Citations
379	Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases. Anticancer Research, 2019, 39, 4273-4277.	0.5	4
380	Impact of planned dose reporting methods on Gamma pass rates for IROC lung and liver motion phantoms treated with pencil beam scanning protons. Radiation Oncology, 2019, 14, 108.	1.2	4
381	Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer. Anticancer Research, 2019, 39, 2569-2574.	0.5	4
382	Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses. Anticancer Research, 2019, 39, 1343-1346.	0.5	4
383	Three-Dimensionally Printed On-Skin Radiation Shields Using High-Density Filament. Practical Radiation Oncology, 2020, 10, e543-e550.	1.1	4
384	Optimizing the Radiotherapy of Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 1559-1560.	0.5	4
385	Extra-cerebral Metastasis â€“ An Independent Predictor of Survival in Older Patients With Brain Metastases Receiving a Local Therapy Plus Whole-Brain Radiotherapy (WBRT). Anticancer Research, 2020, 40, 2841-2845.	0.5	4
386	Palliative Radiotherapy of Primary Glioblastoma. In Vivo, 2021, 35, 483-487.	0.6	4
387	Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy. Anticancer Research, 2021, 41, 5165-5169.	0.5	4
388	Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies. Anticancer Research, 2021, 41, 4407-4410.	0.5	4
389	Palliative Radiotherapy for Cutaneous Squamous Cell Carcinoma of the Head-and-Neck Region. In Vivo, 2021, 35, 2283-2288.	0.6	4
390	Factors Impacting the Overall Survival of Patients Irradiated for Invasive Carcinoma of the Urinary Bladder. In Vivo, 2017, 31, 741-744.	0.6	4
391	Clinical Factors Asssociated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer. In Vivo, 2017, 31, 35-38.	0.6	4
392	Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly. Anticancer Research, 2017, 37, 3287-3290.	0.5	4
393	Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma. Anticancer Research, 2018, 38, 2973-2976.	0.5	4
394	International survey of the treatment of metastatic spinal cord compression. Journal of Radiosurgery and SBRT, 2015, 3, 237-245.	0.2	4
395	Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer. Anticancer Research, 2014, 34, 7309-13.	0.5	4
396	Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. Anticancer Research, 2015, 35, 6793-7.	0.5	4

#	Article	IF	Citations
397	Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer. Anticancer Research, 2016, 36, 803-5.	0.5	4
398	Risk Factors for Sleep Problems Prior to Radiochemotherapy for Malignant Gliomas. In Vivo, 2022, 36, 325-329.	0.6	4
399	Defining the Role of Hemithorax Irradiation for Thymomas Is Difficult. Journal of Thoracic Oncology, 2008, 3, 1-2.	0.5	3
400	Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. BMC Cancer, 2015, 15, 102.	1.1	3
401	Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy. BJU International, 2016, 118, 236-242.	1.3	3
402	Results of a multicenter study investigating the potential impact of the overall treatment time on outcomes of radiation therapy alone with 5Ã—4 Gy for metastatic epidural spinal cord compression. Practical Radiation Oncology, 2017, 7, 137-144.	1.1	3
403	A scoring system to predict local progression-free survival in patients irradiated with 20â€‰Gy in 5 fractions for malignant spinal cord compression. Radiation Oncology, 2018, 13, 257.	1.2	3
404	Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder. Anticancer Research, 2018, 38, 6841-6846.	0.5	3
405	Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM. Anticancer Research, 2019, 39, 1501-1505.	0.5	3
406	Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients. Anticancer Research, 2019, 39, 6217-6222.	0.5	3
407	A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases. Anticancer Research, 2020, 40, 367-371.	0.5	3
408	Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM). Anticancer Research, 2020, 40, 7025-7030.	0.5	3
409	Remaining Lifespan of Patients Aged â‰¥65 Years Receiving Whole-brain Irradiation for Metastases from Cancer of Unknown Primary. Anticancer Research, 2020, 40, 2261-2264.	0.5	3
410	Survival After Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) for Cerebral Metastases in the Elderly. In Vivo, 2020, 34, 1909-1913.	0.6	3
411	Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer. In Vivo, 2020, 34, 679-682.	0.6	3
412	Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast. Anticancer Research, 2020, 40, 2271-2274.	0.5	3
413	Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Journal of Cancer Therapy, 2021, 12, 409-423.	0.1	3
414	Karnofsky Performance Score â€“ An Independent Prognostic Factor of Survival After Palliative Irradiation for Sino-nasal Cancer. Anticancer Research, 2021, 41, 2495-2499.	0.5	3

#	Article	IF	Citations
415	RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2000, , 845.	0.2	3
416	Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers. Anticancer Research, 2016, 36, 4777-4780.	0.5	3
417	An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer. Anticancer Research, 2020, 40, 2257-2260.	0.5	3
418	A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort. Radiology and Oncology, 2019, 53, 219-224.	0.6	3
419	A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder. In Vivo, 2017, 31, 435-438.	0.6	3
420	A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy. In Vivo, 2017, 31, 689-693.	0.6	3
421	Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas. Anticancer Research, 2017, 37, 3729-3733.	0.5	3
422	Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. Anticancer Research, 2018, 38, 1009-1015.	0.5	3
423	Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer. Anticancer Research, 2018, 38, 2391-2394.	0.5	3
424	Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer. Anticancer Research, 2014, 34, 5221-6.	0.5	3
425	Predicting survival of patients with metastatic epidural spinal cord compression from cancer of the head-and-neck. Anticancer Research, 2015, 35, 385-8.	0.5	3
426	A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary. Anticancer Research, 2015, 35, 6219-22.	0.5	3
427	A Total Radiation Dose of 70 Gy Is Required After Macroscopically Incomplete Resection of Squamous Cell Carcinoma of the Head and Neck. Anticancer Research, 2016, 36, 2989-92.	0.5	3
428	Spinal cord compression. European Journal of Cancer, Supplement, 2007, 5, 359-370.	2.2	2
429	A comparison of chemotherapy plus surgery with surgery alone for localized esophageal cancer. Nature Clinical Practice Oncology, 2008, 5, 190-191.	4.3	2
430	Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma. Journal of Dermatology, 2014, 41, 918-921.	0.6	2
431	A matched-pair analysis comparing 5x4 Gy and 10x3 Gy for metastatic spinal cord compression (MSCC) in patients with favorable survival prognoses. Radiation Oncology, 2015, 10, 90.	1.2	2
432	Clinical evaluation of fitness to drive in patients with brain metastases. Neuro-Oncology Practice, 2019, 6, 484-489.	1.0	2

#	Article	IF	Citations
433	Estimating the Lifespan of Elderly Patients With Cerebral Metastases from Kidney Cancer. In Vivo, 2020, 34, 1321-1324.	0.6	2
434	Pre-operative Seizures in Patients With Single Brain Metastasis Treated With Resection Plus Whole-Brain Irradiation and a Boost. In Vivo, 2020, 34, 2705-2709.	0.6	2
435	Development of a multivariable prediction model to estimate the remaining lifespan of elderly patients with cerebral metastases from small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1433-1440.	1.3	2
436	A Simple Implement for Assessing the Survival of Elderly Patients With Melanoma Irradiated for Cerebral Metastases. In Vivo, 2020, 34, 1361-1364.	0.6	2
437	Clinical Prognostic Factors for Local Control and Survival After Irradiation of Grade II Gliomas. In Vivo, 2020, 34, 3719-3722.	0.6	2
438	A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. Anticancer Research, 2021, 41, 379-384.	0.5	2
439	Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose. Journal of Cancer Therapy, 2021, 12, 505-529.	0.1	2
440	A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck. Anticancer Research, 2021, 41, 3055-3058.	0.5	2
441	Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. Anticancer Research, 2016, 36, 4817-4820.	0.5	2
442	Survival Following Palliative External-beam Radiotherapy of Locally Advanced and Metastatic Liver Cancer. Anticancer Research, 2017, 37, 203-206.	0.5	2
443	Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer. Anticancer Research, 2020, 40, 2847-2851.	0.5	2
444	Prognostic Factors in Patients Irradiated for Recurrent Head-and-Neck Cancer. Anticancer Research, 2016, 36, 6547-6550.	0.5	2
445	Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy. In Vivo, 2020, 34, 2727-2731.	0.6	2
446	Re-Evaluation of Prognostic Factors for Survival After Radiotherapy of Cerebral Gliomas: A Supplementary Analysis to a Previous Study. Anticancer Research, 2020, 40, 6513-6515.	0.5	2
447	Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer. In Vivo, 2016, 30, 69-72.	0.6	2
448	Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. Anticancer Research, 2016, 36, 1829-33.	0.5	2
449	Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer. Anticancer Research, 2016, 36, 2523-6.	0.5	2
450	Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with <scp>longâ€term</scp> survival in limited stage <scp>smallâ€cell</scp> lung cancer. Thoracic Cancer, 2022, 13, 925-933.	0.8	2

#	Article	IF	Citations
451	Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience. Cancer Reports, 0, , .	0.6	2
452	Reply to the Role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer, 2010, 116, 3071-3072.	2.0	1
453	Oropharyngeal Cancer Biology and Treatment: Insights From Messenger RNA Sequence Analysis and Transoral Robotic Surgery. Mayo Clinic Proceedings, 2012, 87, 1132.	1.4	1
454	Role of the overall treatment time of radiotherapy with 10ÂÃ—Â3ÂGy for outcomes in patients with metastatic spinal cord compression. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 388-393.	0.9	1
455	The Results of Whole-brain Radiotherapy for Elderly Patients With Brain Metastases from Urinary Bladder Cancer. In Vivo, 2020, 34, 1317-1320.	0.6	1
456	Radiotherapy of Grade III Gliomas: Identification of Clinical Prognostic Factors for Local Tumor Control and Survival. In Vivo, 2020, 34, 3627-3630.	0.6	1
457	Elderly Patients With Single Brain Metastasis â€“ Overall Survival After Surgery Plus Whole-Brain Irradiation and a Radiation Boost. In Vivo, 2020, 34, 1421-1425.	0.6	1
458	A Scoring Tool to Estimate the Survival of Elderly Patients With Brain Metastases from Esophageal Cancer Receiving Whole-brain Irradiation. Anticancer Research, 2020, 40, 1661-1664.	0.5	1
459	Seizures Prior to Whole-brain Irradiation for Metastatic Disease: Prevalence, Risk Factors and Association With Survival. Anticancer Research, 2020, 40, 3429-3434.	0.5	1
460	Interval Between Cancer Diagnosis and Radiotherapy â€“ An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer. In Vivo, 2020, 34, 767-770.	0.6	1
461	A Disease-specific Score for Estimating Survival After Irradiation of Bone Metastases from Colorectal Cancer. Anticancer Research, 2020, 40, 287-291.	0.5	1
462	Technical Note: Multiple energy extraction techniques for synchrotronâ€based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments. Medical Physics, 2021, 48, 4812-4823.	1.6	1
463	Small Cell Lung Cancer. , 2012, , 795-804.		1
464	An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. PLoS ONE, 2016, 11, e0151785.	1.1	1
465	Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer. In Vivo, 2017, 31, 117-120.	0.6	1
466	Occurrence of Seizures Prior to Single-fraction Radiosurgery or Multi-fraction Stereotactic Radiotherapy in Patients With Very Few Brain Metastases. Anticancer Research, 2020, 40, 3499-3504.	0.5	1
467	Estimating the Survival of Elderly Patients with Renal Cell Carcinoma Presenting with Malignant Spinal Cord Compression. Anticancer Research, 2016, 36, 409-13.	0.5	1
468	Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer. Anticancer Research, 2016, 36, 2487-91.	0.5	1

#	Article	IF	Citations
469	Potential Impact of the Overall Treatment Time on Outcomes after Whole-brain Irradiation with 10Ã—3 Gy for Brain Metastases. Anticancer Research, 2016, 36, 3071-4.	0.5	1
470	Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer. Anticancer Research, 2022, 42, 1973-1977.	0.5	1
471	Prognostic Factors of Survival After Radiotherapy for Lung Cancerâ€“The Impact of Smoking Pack Years. In Vivo, 2022, 36, 1297-1301.	0.6	1
472	Prognostic Value of Preclinical Markers after Radiotherapy of Metastatic Spinal Cord Compressionâ€”An Additional Analysis of Patients from Two Prospective Trials. Cancers, 2022, 14, 2547.	1.7	1
473	Regarding postoperative radiotherapy for pathologic stage C prostate cancer: In response to Dr. Lawrence and Mr. Collins. International Journal of Radiation Oncology Biology Physics, 1996, 36, 757-758.	0.4	0
474	Salvage Radiotherapy for Elevated PSA Levels Following Prostatectomy. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	0
475	In response to Drs. Kopelson et al. International Journal of Radiation Oncology Biology Physics, 2003, 55, 282.	0.4	0
476	In response to Dr. Beitler. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1460-1461.	0.4	0
477	In Reply to Dr. Stojkovski. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1605.	0.4	0
478	In Reply to Belderbos et al.. International Journal of Radiation Oncology Biology Physics, 2009, 74, 322-323.	0.4	0
479	Response to the comments on â€œAcute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysisâ€• Oral Oncology, 2010, 46, 889-890.	0.8	0
480	Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Journal of Radiation Oncology, 2013, 2, 309-314.	0.7	0
481	Utilization of PSA measurement at three months following salvage radiation therapy to predict future biochemical outcome. Journal of Radiation Oncology, 2014, 3, 81-87.	0.7	0
482	Best supportive care â€” a reasonable option for patients with brain metastases?. Nature Reviews Clinical Oncology, 2016, 13, 722-724.	12.5	0
483	Reply to D.E. Spratt and N. Szerlip. Journal of Clinical Oncology, 2016, 34, 2677-2678.	0.8	0
484	RE: Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. Journal of the National Cancer Institute, 2016, 108, djv412.	3.0	0
485	Small Cell Lung Cancer. , 2016, , 798-808.e2.		0
486	Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality. Journal of Thoracic Disease, 2018, 10, S2004-S2006.	0.6	0

#	Article	IF	Citations
487	Rational radiotherapy: The role in node-negative squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, , .	0.6	0
488	The PEMBRO-RT phase II randomized trial and the evolution of therapy for metastatic non-small cell lung cancer: a historical perspective. Annals of Translational Medicine, 2019, 7, S294-S294.	0.7	0
489	A Pragmatic Approach to Cancer Staging. International Journal of Radiation Oncology Biology Physics, 2020, 108, 830.	0.4	0
490	Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients. Anticancer Research, 2020, 40, 4081-4086.	0.5	0
491	Regarding Small Cell, Big Dilemma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 865.	0.4	0
492	Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival. Anticancer Research, 2021, 41, 3205-3210.	0.5	0
493	Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy. Radiation Oncology Journal, 2021, 39, 122-128.	0.7	0
494	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. Neuro-Oncology, 2021, 23, i6-i6.	0.6	0
495	Biologically Effective Dose and Rectal Bleeding in Definitive Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2022, 8, 37-46.	0.9	0
496	Pineal Tumors: Fractionated Radiation Therapy Perspective. , 2008, , 371-376.		0
497	Locally Advanced Non-Small Cell Lung Cancer in the Elderly: What Combination of Therapy Is Best?. , 2013, , 173-183.		0
498	Pineal Tumors: Viewpointâ€"Fractionated Radiation Therapy. , 2015, , 469-476.		0
499	Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer. Anticancer Research, 2017, 37, 2537-2540.	0.5	0
500	Metastatic Epidural Spinal Cord Compression: Conventional Radiotherapy. , 2018, , 159-176.		0
501	A New Scoring-system for Estimating Overall Survival After Radiotherapy of Recurrent Head and Neck Cancers. Anticancer Research, 2018, 38, 1611-1613.	0.5	0
502	Defining the Optimal Dose of Stereotactic Radiosurgery for Treating Cerebral Metastases in Elderly Patients. Anticancer Research, 2015, 35, 5701-4.	0.5	0
503	Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. Anticancer Research, 2016, 36, 375-8.	0.5	0
504	Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer. Anticancer Research, 2016, 36, 1089-91.	0.5	0